Intervertebral Disc Disease

Gleamer, leading company in AI medical imaging, today announces that it acquires Pixyl, a pioneer in FDA- and CE-cleared Neuro MRI applications, and Caerus Medical, developer of cutting-edge Lumbar MRI AI solutions. These strategic acquisitions position Gleamer as the only AI provider with an unmatched, proprietary suite of solutions covering all core imaging modalities—X-ray, Mammography, CT, and now, MRI—further solidifying its leadership in the radiology AI market. With its robust portfolio, Gleamer is redefining the future of AI-powered radiology, providing radiologists with best-in-class tools that optimize efficiency, enhance diagnostic accuracy, and accelerate patient care. This latest expansion ensures that Gleamer remains the first choice for institutions seeking comprehensive AI integration across their imaging workflows. “With the addition of Pixyl and Caerus Medical, Gleamer now offers the most extensive proprietary AI-driven imaging portfolio in the industry. This move marks a transformative leap forward, empowering radiologists with cutting-edge MRI applications while strengthening our leadership in medical imaging AI,” said Christian Allouche, CEO & co-founder of Gleamer. “These acquisitions underscore our unwavering commitment to revolutionizing radiology, accelerating the adoption of AI, and delivering superior diagnostic precision.” Pixyl, an award-winning innovator in brain MRI analysis, is recognized for its flagship product Pixyl.Neuro, which has already gained significant traction. The software enables the early detection of neuroinflammatory and neurodegenerative conditions, including Alzheimer’s disease, unlocking life-changing opportunities for early intervention. With new reimbursement pathways emerging in the U.S., Pixyl’s solutions are poised for rapid adoption, reinforcing its role at the forefront of AI-driven radiology innovation. “Joining Gleamer amplifies the impact of our technology, bringing our breakthrough MRI applications to a global audience,” said Senan Doyle, CEO of Pixyl. “Together, we are setting new standards in AI-powered radiology and driving the future of neuroimaging.” Caerus Medical’s AI technology revolutionizes lumbar spine MRI interpretation, offering unparalleled precision in detecting all relevant findings (disc herniation, stenosis, spondylolisthesis etc.). This comprehensive approach enhances workflow efficiency and diagnostic reliability, streamlining the reporting process for radiologists. “The Caerus Medical team is thrilled to become part of Gleamer, the leader in AI-powered radiology,” said David Vittecoq, CEO of Caerus Medical. “This collaboration will fast-track the deployment of our lumbar MRI application and drive groundbreaking advancements in musculoskeletal imaging.” With these acquisitions, Gleamer’s global workforce surpasses 100 employees across seven countries, bolstering its MRI research and development efforts. The integration of Pixyl and Caerus Medical within Gleamer’s AI Factory will accelerate innovation, ensuring the rapid deployment of next-generation imaging solutions that meet the evolving needs of modern radiology.

FRIDAY, Feb. 21, 2025 -- There is some evidence for epidural steroid injections (ESIs) reducing pain and disability in cervical and lumbar radiculopathies and possibly in lumbar spinal stenosis, according to a study published online Feb. 12 in Neurology . Carmel Armon, M.D., from Loma Linda University School of Medicine in California, and colleagues conducted a systematic review to evaluate the use of ESIs in cervical and lumbar spinal stenosis and radiculopathies. Due to the variability in efficacy measures, differences based on any measure of success were reported as the success rate difference (SRD). Ninety randomized controlled trials met the inclusion criteria. The researchers found that ESIs probably reduced short-term pain (SRD, −24.0 percent; number needed to treat [NNT], 4) and disability (SRD, −16.0 percent; NNT, 6) and possibly reduced long-term disability (SRD, −11.1 percent; NNT, 9) in cervical and lumbar radiculopathies. The evidence was insufficient to determine whether ESIs reduced long-term pain in radiculopathies. ESIs possibly reduced short-term (SRD, −26.2 percent; NNT, 4) and long-term (SRD, −11.8 percent; NNT, 8) disability in lumbar spinal stenosis, but there was no reduction in short-term pain; insufficient evidence was seen for determining whether ESIs reduced long-term pain. The evidence was insufficient for determining the effectiveness of ESIs in cervical spinal stenosis. "The systematic review found evidence that ESIs are probably effective in reducing short-term pain and disability caused by radiculopathy and possibly effective in reducing short-term disability, but not pain, in lumbar spinal stenosis," the authors write. Several authors disclosed ties to industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

MINNEAPOLIS, Feb. 19, 2025 /PRNewswire/ -- The American Academy of Neurology (AAN) has developed a new systematic review to summarize for neurologists and other clinicians the evidence for epidural steroid injections and whether they reduce pain and disability for people with certain kinds of chronic back pain. The systematic review is published in the February 12, 2025, online issue of Neurology®. It updates a 2007 assessment by the AAN. With an epidural steroid injection, a steroid or corticosteroid medication is injected into a part of the spine called the epidural space. The goal is to help reduce certain kinds of back pain. "Chronic back pain is common and can negatively impact a person's quality of life, making it difficult to move, sleep and participate in daily activities," said author Carmel Armon, MD, of Loma Linda University School of Medicine in California and a Fellow of the American Academy of Neurology. "In our review, studies show epidural steroid injections may have limited efficacy. They may modestly reduce pain in some situations for up to three months and reduce disability for some people for up to six months or more." For the review, researchers analyzed all available studies over a 16-year period. A total of 90 studies were examined. The review focused on the use of epidural steroid injections to reduce pain for people with radiculopathy and spinal stenosis. Radiculopathy is a condition caused by a pinched nerve in your spine. Spinal stenosis is a condition where your spinal cord or nerves have become compressed because the space around your spinal cord has become too small. For people with radiculopathy, the review says studies show epidural steroid injections may be effective at modestly reducing pain and disability for up to three months after the procedure. When compared to people not receiving the treatment, 24% more people receiving the treatment reported reduced pain, and 16% more reported reduced disability for up to 3 months. The treatment may also reduce disability for up to six months or more, with 11% more of those treated reporting reduced disability. Most of the reviewed studies looked at people with radiculopathy in their lower backs, so it is unclear how effective the treatment is for those with radiculopathy in their necks. For people with spinal stenosis, studies show epidural steroid injections might modestly reduce disability for up to six months or more after the procedure. When compared to people not receiving the treatment, 26% more people receiving the treatment reported reduced disability up to three months, and 12% more for up to six months or more. The treatment was not found to reduce pain for up to three months. All studies looked at people with stenosis in their lower backs, so researchers do not know how effective the treatment is for people with stenosis in their necks. "Our review affirms the limited effectiveness of epidural steroid injections in the short term for some forms of chronic back pain," said author Pushpa Narayanaswami, MD, of Beth Israel Deaconess Medical Center in Boston and a Fellow of the American Academy of Neurology. "We found no studies looking at whether repeated treatments are effective or examining the effect of treatment on daily living and returning to work. Future studies should address these gaps." Discover more about brain health at BrainandLife.org, from the American Academy of Neurology. This resource also offers a magazine, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world's leading experts in brain health. Follow Brain & Life® on Facebook, X and Instagram. The American Academy of Neurology is the leading voice in brain health. As the world's largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN's mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine. Explore the latest in neurological disease and brain health from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn and YouTube. SOURCE American Academy of Neurology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED